Related Experiment Videos
Dobesilate is an angiogenesis inhibitor
Pedro Cuevas1, I Sanchez, R M Lozano
1Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid, Spain. pedro.cuevas@hrc.es
European Journal of Medical Research
|September 27, 2005
Summary
Dobesilate, an oral medication, significantly inhibited blood vessel formation in a mouse model. This suggests its potential as a novel antiangiogenic therapy for various cancers and other angiogenesis-dependent diseases.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Aberrant angiogenesis fuels tumor progression in solid tumors and hematological malignancies.
- Antiangiogenic therapy presents a promising strategy for treating these diseases.
- Dobesilate is an established oral agent for managing vascular issues in diabetic retinopathy.
Purpose of the Study:
- To investigate the antiangiogenic potential of dobesilate.
- To determine if dobesilate interferes with the process of neovascularization.
- To explore dobesilate as a therapeutic agent for angiogenesis-dependent diseases.
Main Methods:
- A mouse gelatine sponge assay was employed to assess angiogenesis.
- Acidic fibroblast growth factor (aFGF) was used as an inducer of neovascularization.
- The effect of dobesilate on vessel ingrowth was quantified in vivo.
Main Results:
- Dobesilate demonstrated a remarkable reduction in vessel ingrowth within aFGF-containing sponges.
- The compound effectively inhibited neovascularization induced by aFGF in the mouse model.
- Quantitative analysis confirmed the antiangiogenic effect of dobesilate.
Conclusions:
- Dobesilate exhibits significant antiangiogenic properties.
- These findings support the potential of dobesilate as a therapeutic agent for angiogenesis-dependent diseases.
- Further research into dobesilate for treating FGF-mediated angiogenesis-related conditions is warranted.